EFB Dengue Literature Review

XBP1

5 min read

XBP1

Overview

XBP1 is the transcription factor mediating the unfolded protein response and is required for the secretory apparatus of plasma cells. It earns a page not because the wiki has deep evidence about it, but because the sources disagree about it in an informative way: XBP1 is reported as highly expressed in murine T-bet⁺CD11c⁺ B cells, as a negative result in human atypical B cells, as a DN3-defining signature, and as negatively enriched in DN2 cells.

That spread is a useful proxy for a larger question — how far along the plasma-cell differentiation path these cells actually are.

Key Points from Literature

  • Xbp1 was among the genes most highly expressed in murine T-bet⁺CD11c⁺ B cells relative to GC and naive B cells, alongside Prdm1 (Blimp-1), Zeb2, Bhlhe41, Zbtb32, Tnfrsf17 (BCMA) and Sdc1 (CD138) — an ASC-leaning signature (see Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells, murine RNA-seq, day 12 post-LCMV)

  • In human atypical B cells, XBP1 — along with IRF4 and PRDM1 — was a negative result (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, human, core n=4 10x scRNA-seq)

  • In acute dengue, XBP-1 target genes were significantly enriched in patients with low viral load (late illness), which the authors interpret as the UPR driving plasma cell differentiation — consistent with plasmablast numbers correlating with duration of illness (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, n=28 acute secondary dengue, whole-blood microarray + GSEA)

  • The UPR is invoked as a DN3-defining signature (see Lamprinou2026 - ABCs and DN B Cells, review). See DN3 B Cell.

  • The UPR gene set was negatively enriched in DN2 cells (see Scharer2019 - Epigenetic Programming in SLE B Cells, human, GSEA)

  • ★ [2026-08-28] The primary data behind “UPR = DN3” — and it puts the UPR signature on the CD11c-negative side of the DN compartment. Sorted DN1–DN4 from IgG4-RD blood, profiled by bulk transcriptomics (n=4), showed DN3 alone enriched for the unfolded protein response together with proliferation, plus antibody-secreting-cell features and high IGHG4 message — “the only B cells transcriptomically enriched for IgG4”. The wiki previously held the UPR→DN3 claim only on a review’s authority (Lamprinou2026 - ABCs and DN B Cells); this is the measurement under it. Two limits travel with it: XBP1 itself is not named — the evidence is gene-set enrichment at pathway level, not an XBP1 transcript or protein measurement — and the finding is transcriptomic, not lineage-tracing (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=4 sorted, human).

Contradictions & Debates

★ Is XBP1 up or down in atypical B cells?

SourceSystemFinding
Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B CellsMurine, bulk RNA-seq, T-bet⁺CD11c⁺Xbp1 highly expressed
Sutton2021 - Alternative Lineage B Cells in Vaccination and InfectionHuman, scRNA-seq, atypical B cellsXBP1 negative (with IRF4, PRDM1)
Scharer2019 - Epigenetic Programming in SLE B CellsHuman, DN2UPR gene set negatively enriched
Lamprinou2026 - ABCs and DN B CellsReviewUPR is a DN3 signature
Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed TissuesHuman, bulk RNA-seq of sorted DN1–DN4 (n=4)UPR enriched in DN3 only, not DN1/DN2/DN4

★ [2026-08-28] Read on the CD11c axis, three of these four rows agree. CD11c is the one marker the two published DN gating schemes share — Emory/Sanz cut DN on CD21 × CD11c, Pillai/Allard-Chamard on CXCR5 × CD11c — and on that shared axis the picture is consistent: the UPR/ASC signature sits with the CD11c⁻ DN cells (Allard-Chamard’s DN3) and is absent from the CD11c⁺ DN cells (Scharer’s DN2, where the UPR set is negatively enriched). Song2022’s Xbp1-high cells are the apparent exception, and they are murine CD11c⁺ — which is what makes candidate reconciliation 1 (species) and 3 (timepoint) the live ones rather than 2.

⚠ But do not read the two “DN3” labels as interchangeable. Allard-Chamard’s DN3 is CXCR5⁻CD11c⁻ with no CD21 in the panel; the wiki’s and Emory’s DN3 is CD11c⁻CD21⁻. Both are CD11c⁻, so the coarse statement above survives — but which CD11c⁻ DN cells carry the UPR signature is axis-dependent and unresolved. In Allard-Chamard’s scheme the CD11c⁻ DN pool splits into DN1 (CXCR5⁺) and DN3 (CXCR5⁻) and only the latter is UPR-high; whether a CD21-based DN3 gate captures the same cells has never been tested. See DN3 B Cell and DN2 Gating Strategy.

Candidate reconciliations, none tested:

  1. Species. Murine T-bet⁺CD11c⁺ and human DN2 may simply differ; this is the same caution that applies across the ABC/DN2 mapping generally.
  2. Population. If UPR marks DN3 rather than DN2 (Lamprinou2026, now with Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues as the primary underneath it), then a bulk murine “T-bet⁺CD11c⁺” gate spanning several DN-equivalent states would show Xbp1 high while a purified human DN2 gate showed it low. This would make the disagreement an artefact of gate breadth, not biology. ⚠ This reconciliation is now the weakest of the three, not the strongest: Allard-Chamard’s DN3 is CD11c⁻, so a CD11c⁺ murine gate — however broad — should exclude the UPR-high cells rather than dilute them in.
  3. Timepoint. Song2022 sampled at day 12 during resolution, when its cells already contained antibody-secreting cells; Sutton2021 and Scharer2019 profiled steady-state or vaccination-response cells.

The wiki records this as open. It bears directly on the BLIMP-1 question already tracked — whether these cells are pre-ASCs poised to secrete or a distinct non-secretory state — and on the unresolved T-bet→BLIMP-1 relationship.

BLIMP-1, IRF4, Plasmablast, DN2 B Cell, DN3 B Cell, Atypical B Cell, Atypical B Cell Effector Output, Age-Associated B Cell, CD11c, CXCR5

Sources

Graph View

Backlinks